著者: Veasey-RodriguesHeloisa, ParsonsHenrique A, JankuFilip, NaingAung, WhelerJennifer J, TsimberidouApostolia M, KurzrockRazelle

原題: A pilot study of temsirolimus and body composition.

著者: GuevremontCatherine, AlaskerAhmed, KarakiewiczPierre I

原題: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

著者: MassardChristophe, PatardJean-Jacques, HermineOlivier, RavaudAlain

原題: [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects].

著者: P JGoebell, AMünch, LMüller, H JHurtz, MKoska, SBusies, NMarschner

原題: A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.

著者: EkshyyanOleksandr, MillsGlenn M, LianTimothy, AmirghahariNazanin, RongXiaohua, Lowery-NordbergMary, AbreoFleurette, VeillonDiana M, CalditoGloria, SpeicherLisa, GlassJonathan, NathanCherie-Ann O

原題: Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.

著者: EidenAdrian M, ZhangShuling, GaryJoy M, SimmonsJohn K, MockBeverly A

原題: Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

著者: JerusalemGuy, RoriveAndree, CollignonJoelle

原題: Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.

著者: HutsonThomas E, FiglinRobert A, KuhnJohn G, MotzerRobert J

原題: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

著者: JobardElodie, BlancEllen, NégrierSylvie, EscudierBernard, GravisGwenaelle, ChevreauChristine, Elena-HerrmannBénédicte, TrédanOlivier

原題: A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

著者: GolčićMarin, PetkovićMarija

原題: Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?

著者: KimKi Hyang, KimJoo Hoon, LeeJi Young, KimHyo Song, HeoSu Jin, KimJi Hyung, KimHo Young, RhaSun Young

原題: Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.

著者: SingletonPatrick A, MambetsarievNurbek, LennonFrances E, MathewBiji, SieglerJessica H, Moreno-VinascoLiliana, SalgiaRavi, MossJonathan, GarciaJoe Gn

原題: Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.

著者: PortaCamillo, SzczylikCezary

原題: Tolerability of first-line therapy for metastatic renal cell carcinoma.

著者: KuhnJohn G, ChangSusan M, WenPatrick Y, CloughesyTimothy F, GreenbergHarry, SchiffDavid, ConradCharles, FinkKaren L, RobinsH Ian, MehtaMinesh, DeAngelisLisa, RaizerJeffrey, HessKenneth, LambornKathleen R, DanceyJanet, PradosMichael D,

原題: Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

著者: WoodLaura S

原題: New therapeutic strategies for renal cell carcinoma.

著者: HussarDaniel A

原題: New drugs08, part 2.

著者: PuighermanalEmma, Busquets-GarciaArnau, Gomis-GonzálezMaria, MarsicanoGiovanni, MaldonadoRafael, OzaitaAndrés

原題: Dissociation of the pharmacological effects of THC by mTOR blockade.

著者: MoroneyJohn, FuSiqing, MoulderStacy, FalchookGerald, HelgasonThorunn, LevenbackCharles, HongDavid, NaingAung, WhelerJennifer, KurzrockRazelle

原題: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.

著者: CornuJ-N, RouprêtM, BensalahK, OudardS, PatardJ-J

原題: [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].

著者: PouesselDamien, CulineStéphane, VerhoestGregory, PatardJean-Jacques

原題: [Renal cell carcinoma and antiangiogenic therapies].

著者: SchmidingerManuela, ZielinskiChristoph C

原題: Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

著者: MizutaniKosuke, ItoToshiki, TakaharaKiyoshi, AndoRyosuke, IshiharaTakuma, YasuiTakahiro, ShirokiRyoichi, MiyakeHideaki, KoieTakuya

原題: Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.

著者: WangDenise, EisenHoward J

原題: Mechanistic Target of Rapamycin (mTOR) Inhibitors.

著者: MarschnerNorbert, MüllerLothar, MünchAxel, BlumenstengelKlaus, HutzschenreuterUlrich, BusiesSabine

原題: Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

著者: FahimAmmad, RehmanZaira, BhattiMuhammad Faraz, VirkNasar, AliAmjad, RashidAmir, ParachaRehan Zafar

原題: The Route to 'Chemobrain' - Computational probing of neuronal LTP pathway.

著者: KaravasilisVasilios, SamantasEpaminontas, KoliouGeorgia-Angeliki, Kalogera-FountzilaAnna, PentheroudakisGeorge, VarthalitisIoannis, LinardouHelena, RallisGrigorios, SkondraMaria, PapadopoulosGeorgios, PapatsibasGeorge, SgourosJoseph, GoudopoulouAthina, KalogerasKonstantine T, DervenisChristos, PectasidesDimitrios, FountzilasGeorge

原題: Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.

著者: BoyleH, NégrierS

原題: Addition of bevacizumab to temsirolimus in kidney cancer patients.

著者: BhojaniNaeem, JeldresClaudio, PatardJean-Jacques, PerrottePaul, SuardiNazareno, HuttererGeorg, PatenaudeFrançois, OudardStéphane, KarakiewiczPierre I

原題: Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

著者: TreiberGerhard

原題: mTOR inhibitors for hepatocellular cancer: a forward-moving target.

著者: KuruTimur Hasan, HuberJohannes, HatibogluGencay, WagenerNina, PahernikSascha, HadaschikBoris, HohenfellnerMarkus

原題: Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.